Positive Response to Fluorouracil and Oxaliplatin in Signet Ring Cell Adenocarcinoma of the Bladder Presenting with Retroperitoneal Fibrosis

Abstract

Bladder adenocarcinoma is an uncommon type of bladder cancer. Signet ring cell pathology is a rare subtype of bladder adenocarcinoma. Global incidence rates of signet ring cell adenocarcinoma of the bladder have not been established. Management of signet cell bladder cancer is challenging as it is aggressive in behavior with frequent relapse despite chemotherapy. Here we present a case of stage IV signet cell bladder cancer with retroperitoneal fibrosis treated with FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin) regimen with a complete durable response.

Primary signet-ring cell carcinoma of the bladder treated with laparoscopic radical cystectomy: a case report

“…We considered that NAC is also effective for this case with signet ring cell carcinoma, which is one of variant of UC. Table 1 shows the regimens used in 12 cases of bladder signet-ring cell carcinoma treated with chemotherapy [4,6,[10][11][12][13][14][15][16][17][18]. However, these reports were not about neoadjuvant therapy, but about adjuvant therapy or systemic therapy for metastatic disease.…”